Description: Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics that stimulate or restore muscle regeneration in severe disorders. Its lead program focuses on the development of a therapeutic for correcting the impaired muscle regenerative process in genetic pediatric disease, duchenne muscular dystrophy (DMD), a genetic disease that involves the mutation and functional disruption of the DMD gene and loss of Dystrophin. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Home Page: satellos.com
65 Front Street East
Toronto,
ON
M5E 1B5
Canada
Phone:
647 660 1780
Officers
| Name | Title |
|---|---|
| Mr. Francis Gleeson B.B.A. M.B.A | Co-Founder, CEO, Pres & Director |
| Dr. Michael A. Rudnicki Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Warren Whitehead C.M.A., CPA | Chief Financial Officer |
| Mr. William Wasyl Jarosz | Exec. Director |
| Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA | Strategic Advisor |
| Dr. Philip Lambert M.A., Ph.D. | Chief Technology Officer |
| Mr. J. Robert Hall CFA | VP of Fin. & Admin. |
Exchange: OTCQB
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0993 |
| Price-to-Sales TTM: | 295.3351 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |